Cost-Effectiveness Analysis of Adjuvant Pertuzumab and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer in Japan
The economic viability of dual HER2-targeted therapy was most pronounced in patients with node-positive high-risk early breast cancer. This study highlights the potential of dual HER2-targeted therapy as a cost-effective addition for these cases.
Authors
- So Sato (ORCID: https://orcid.org/0000-0003-1265-6835)
- Hayato Yamana (ORCID: https://orcid.org/0000-0003-2214-6695)
- Hideo Yasunaga (ORCID: https://orcid.org/0000-0002-6017-469X)
- Takaaki Konishi (ORCID: https://orcid.org/0000-0002-9538-4419)
- Hideaki Watanabe (ORCID: https://orcid.org/0000-0002-3925-2665)
- Chanon Nusawat (ORCID: https://orcid.org/0009-0009-2716-3727)
Institutions
- Jichi Medical University (JP)
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1007/s40261-024-01399-3
- Citations
- 3
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Ministry of Health, Labour and Welfare
- University of Tokyo